Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Genvor Inc​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
G

Genvor Inc

Ask AI
Doc SearchProfileEntity Structure

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Genvor Inc​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
G

Genvor Inc

Ask AI
Doc SearchProfileEntity Structure

Overview

ProfileEntity Structure

Documents

SEC Filings

Genvor Inc — Company Profile

Genvor Inc is a company headquartered in HENDERSON. SEC filings classify the company under SIC 0100.

Headquarters
HENDERSON, NV

Key Metrics

Price
$0.00
Market Cap
$0.00
Revenue (TTM)
$0.00
Net Income (TTM)
$0.00
EPS (TTM)
0.00
P/E (TTM)
0.00
P/B (TTM)
0.00
Dividend Yield
0.00%
ROE (TTM)
0.00%
ROA (TTM)
0.00%
Operating Margin
0.00%
Beta
0.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(103)

Expand
  • 4Yates Clayton Clopton12:53PM
  • 8-KEntry into a Material Definitive Agreement26 Oct
  • 8-KEntry into a Material Definitive Agreement19 Oct
  • 10-QQ3ended 30 Jun 202614 Aug
  • DEF 14CDEFINITIVE INFORMATION STATEMENT31 Jul
  • PRE 14CPRELIMINARY INFORMATION STATEMENT20 Jul
  • 8-KEntry into a Material Definitive Agreement22 Jun
  • 3Kalkofen Donald A.26 May
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers21 May
  • 10-QQ2ended 31 Mar 202613 May
  • 8-KUnregistered Sales of Equity Securities11 May
  • 8-KEntry into a Material Definitive Agreement22 Apr
  • 4Pawlak Chad Lee Sr.16 Apr
  • 4Pawlak Chad Lee Sr.14 Apr
  • 10-Q/AQ1ended 31 Dec 202513 Mar
  • 10-QQ1ended 31 Dec 202512 Feb
  • 4Pawlak Chad Lee Sr.9 Jan
  • 10-KFY 2025ended 30 Sept 202510 Dec 2025
  • D<ITEMS>06c5 Dec 2025
  • 4Jaynes Jessee M5 Dec 2025

Mentions in Filings

  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    IMPACT BIOMEDICAL INC.Genvor Inc·DEFM14A - Definitive proxy statement (merger)·Q4 26·26 Oct
  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    Zoar LtdGenvor Inc·424B3 - Prospectus filing (Rule 424(b)(3))·Q3 27·26 Oct
  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    Zoar LtdGenvor Inc·F-4/A - Registration statement (business combination, foreign issuer, amendment)·Q3 27·21 Oct
  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    Zoar LtdGenvor Inc·F-4/A - Registration statement (business combination, foreign issuer, amendment)·Q3 27·2 Oct
  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    Zoar LtdGenvor Inc·F-4 - Registration statement (business combination, foreign issuer)·Q2 27·10 Sep

Genvor Inc — Company Profile

Genvor Inc is a company headquartered in HENDERSON. SEC filings classify the company under SIC 0100.

Headquarters
HENDERSON, NV

Key Metrics

Price
$0.00
Market Cap
$0.00
Revenue (TTM)
$0.00
Net Income (TTM)
$0.00
EPS (TTM)
0.00
P/E (TTM)
0.00
P/B (TTM)
0.00
Dividend Yield
0.00%
ROE (TTM)
0.00%
ROA (TTM)
0.00%
Operating Margin
0.00%
Beta
0.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(103)

Expand
  • 4Yates Clayton Clopton12:53PM
  • 8-KEntry into a Material Definitive Agreement26 Oct
  • 8-KEntry into a Material Definitive Agreement19 Oct
  • 10-QQ3ended 30 Jun 202614 Aug
  • DEF 14CDEFINITIVE INFORMATION STATEMENT31 Jul
  • PRE 14CPRELIMINARY INFORMATION STATEMENT20 Jul
  • 8-KEntry into a Material Definitive Agreement22 Jun
  • 3Kalkofen Donald A.26 May
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers21 May
  • 10-QQ2ended 31 Mar 202613 May
  • 8-KUnregistered Sales of Equity Securities11 May
  • 8-KEntry into a Material Definitive Agreement22 Apr
  • 4Pawlak Chad Lee Sr.16 Apr
  • 4Pawlak Chad Lee Sr.14 Apr
  • 10-Q/AQ1ended 31 Dec 202513 Mar
  • 10-QQ1ended 31 Dec 202512 Feb
  • 4Pawlak Chad Lee Sr.9 Jan
  • 10-KFY 2025ended 30 Sept 202510 Dec 2025
  • D<ITEMS>06c5 Dec 2025
  • 4Jaynes Jessee M5 Dec 2025

Mentions in Filings

  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    IMPACT BIOMEDICAL INC.Genvor Inc·DEFM14A - Definitive proxy statement (merger)·Q4 26·26 Oct
  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    Zoar LtdGenvor Inc·424B3 - Prospectus filing (Rule 424(b)(3))·Q3 27·26 Oct
  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    Zoar LtdGenvor Inc·F-4/A - Registration statement (business combination, foreign issuer, amendment)·Q3 27·21 Oct
  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    Zoar LtdGenvor Inc·F-4/A - Registration statement (business combination, foreign issuer, amendment)·Q3 27·2 Oct
  • G
    … ology sectors, with experience in capital markets transactions, SEC reporting, U.S. GAAP compliance, internal controls and investor relations. Since May 2026, Mr. Kalkofen has served as Acting Chief Financial Officer of <strong>Genvor Inc</strong>orporated (OTCQB: GNVR), a biotechnology company, through Wave Financial Consulting LLC, and since October 2022, he has served as principal and sole owner of Wave Financial Consulting LLC, a financial consulting practice …
    Zoar LtdGenvor Inc·F-4 - Registration statement (business combination, foreign issuer)·Q2 27·10 Sep